Through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia Vancouver, British Columbia, Canada–Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British
Vancouver, British Columbia, Canada– Andira Pharmaceuticals is proud to welcome Janette Lyons as Chief Financial Officer (CFO). Janette is a senior finance and business leader with over 15 years of executive financial management experience. She brings to Andira an impressive track record of success working in start-ups, multinational, crown corporation,
Andira CEO Dana Lambert, PhD says, “I wanted to take the opportunity to recognize Dr. Claudia Dietrich and her outstanding achievements as a research scientist on our team. She is a talented and highly motivated professional and has been a driving force behind the successful development of our wound care
VANCOUVER, BC, May 31, 2022 – Andira Pharmaceuticals is proud to announce the hiring of Eurofins Discovery to conduct pre-clinical research on Andira’s lead asset, a cannabinoid-based injectable antibiotic for treatment of hospital-acquired infection. Eurofins Discovery is the leading contract research organization (CRO) brand with over 35 years of success
Vancouver, BC – Andira Pharmaceuticals is pleased to welcome Ryan Miller to the Advisory Board. Mr. Miller is a finance veteran with over 15 years of experience in Corporate Finance, Technology, and Energy. After serving as CFO and VP of Finance for several large Canadian companies, Mr. Miller started his
Vancouver, BC Canada – Andira Pharmaceuticals is pleased to announce it has retained MCRA LLC, a world leading global medical device, regulatory and clinical research consulting firm based in Washington, DC, to consult and provide guidance during the regulatory approval process for its anti-microbial wound care adhesive which offers significantly
Vancouver, July 8, 2021– Andira Pharmaceuticals (“Andira”) has been awarded two consecutive Mitacs Accelerate Internship grants to advance anti-infective R&D within the Prof. Charles Thompson Laboratory at the University of British Columbia (UBC) Department of Microbiology and Immunology. Both Mitacs grants directly support Dr. Claudia Dietrich, a UBC research scientist,
Vancouver, July 7, 2021– Andira Pharmaceuticals today announces it has secured an exclusive worldwide license for a portfolio of three cannabinoid antibiotic technologies along with their complementary drug delivery systems designed to prevent and treat multi-drug resistant infections. The license was granted by the University of British Columbia (UBC). Inventors
Vancouver, British Columbia, Canada– Andira Pharmaceuticals welcomes to its board of directors, Dr. Ethan Russo, a global pioneer in the development of cannabinoid therapeutics. Andira is a privately-held biopharmaceutical firm dedicated to the advancement of cannabinoid-based therapeutics for infectious disease and oncology indications in the traditional pharmaceutical business model. Andira
Vancouver, British Columbia, Canada– To protect novel anti-infective formulations developed at The University of British Columbia (UBC) for the treatment of Enterococcus, including the multi-drug-resistant superbug VRE, a Patent Cooperation Treaty (PCT) application entitled “Antibiotic Cannabinoid-Terpene Formulations” was filed in May 2020. The International Search Report & Written Opinion (ISR/WO)
Through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia Vancouver, British Columbia, Canada–Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British
Vancouver, British Columbia, Canada– Andira Pharmaceuticals is proud to welcome Janette Lyons as Chief Financial Officer (CFO). Janette is a senior finance and business leader with over 15 years of executive financial management experience. She brings to Andira an impressive track record of success working in start-ups, multinational, crown corporation,
Andira CEO Dana Lambert, PhD says, “I wanted to take the opportunity to recognize Dr. Claudia Dietrich and her outstanding achievements as a research scientist on our team. She is a talented and highly motivated professional and has been a driving force behind the successful development of our wound care
VANCOUVER, BC, May 31, 2022 – Andira Pharmaceuticals is proud to announce the hiring of Eurofins Discovery to conduct pre-clinical research on Andira’s lead asset, a cannabinoid-based injectable antibiotic for treatment of hospital-acquired infection. Eurofins Discovery is the leading contract research organization (CRO) brand with over 35 years of success
Vancouver, BC – Andira Pharmaceuticals is pleased to welcome Ryan Miller to the Advisory Board. Mr. Miller is a finance veteran with over 15 years of experience in Corporate Finance, Technology, and Energy. After serving as CFO and VP of Finance for several large Canadian companies, Mr. Miller started his
Vancouver, BC Canada – Andira Pharmaceuticals is pleased to announce it has retained MCRA LLC, a world leading global medical device, regulatory and clinical research consulting firm based in Washington, DC, to consult and provide guidance during the regulatory approval process for its anti-microbial wound care adhesive which offers significantly
Vancouver, July 8, 2021– Andira Pharmaceuticals (“Andira”) has been awarded two consecutive Mitacs Accelerate Internship grants to advance anti-infective R&D within the Prof. Charles Thompson Laboratory at the University of British Columbia (UBC) Department of Microbiology and Immunology. Both Mitacs grants directly support Dr. Claudia Dietrich, a UBC research scientist,
Vancouver, July 7, 2021– Andira Pharmaceuticals today announces it has secured an exclusive worldwide license for a portfolio of three cannabinoid antibiotic technologies along with their complementary drug delivery systems designed to prevent and treat multi-drug resistant infections. The license was granted by the University of British Columbia (UBC). Inventors
Vancouver, British Columbia, Canada– Andira Pharmaceuticals welcomes to its board of directors, Dr. Ethan Russo, a global pioneer in the development of cannabinoid therapeutics. Andira is a privately-held biopharmaceutical firm dedicated to the advancement of cannabinoid-based therapeutics for infectious disease and oncology indications in the traditional pharmaceutical business model. Andira
Vancouver, British Columbia, Canada– To protect novel anti-infective formulations developed at The University of British Columbia (UBC) for the treatment of Enterococcus, including the multi-drug-resistant superbug VRE, a Patent Cooperation Treaty (PCT) application entitled “Antibiotic Cannabinoid-Terpene Formulations” was filed in May 2020. The International Search Report & Written Opinion (ISR/WO)
Andira is a private healthcare company leveraging natural drug substances to improve lives and address critical illnesses. The company is advancing urgently needed solutions for highly prevalent medical indications in three areas: hospital acquired infection, oncology and dermatology.
Join our mailing list for our periodic general business, fundraising and scientific updates.
Copyright © 2023 Andira Pharmaceuticals
